The COVID-19 crisis has increased the adoption of artificial intelligence in clinical oncology trials. Here’s what it means for patient recruitment, retention and outcomes.

With clinical oncology trials put on hold during the COVID-19 pandemic, researchers turned to troves of data to find patients across the country who would qualify for trials, even if they weren’t physically there.

Artificial intelligence enabled this process, and may have created a move toward decentralized trials that potentially could last long after the pandemic is over.

Jeff Elton is CEO of ConcertAI, which works with some of the biggest oncology pharmaceutical companies and research organizations. Healthcare IT News interviewed Elton to get his thoughts on this shift and what it means for both treatments and patient outcomes.